Patents by Inventor Robert Steven Kania

Robert Steven Kania has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cycloalkyl-Linked Diheterocycle Derivatives
    Publication number: 20190040055
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: October 11, 2018
    Publication date: February 7, 2019
    Applicant: Pfizer Inc.
    Inventors: Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Robert Louis Hoffman, Peter Qinhua Huang, Robert Steven Kania, Pei-Pei Kung, Maria Angelica Linton, Lakshmi Sourirajan Narasimhan, Paul Francis Richardson, Daniel Tyler Richter, Graham Smith
  • Cycloalkyl-linked diheterocycle derivatives
    Patent number: 10125130
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: November 13, 2018
    Assignee: Pfizer Inc.
    Inventors: Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Robert Louis Hoffman, Peter Qinhua Huang, Robert Steven Kania, Pei-Pei Kung, Maria Angelica Linton, Lakshmi Sourirajan Narasimhan, Paul Francis Richardson, Daniel Tyler Richter, Graham Smith
  • Cycloalkyl-Linked Diheterocycle Derivatives
    Publication number: 20180148441
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: November 29, 2017
    Publication date: May 31, 2018
    Applicant: PFIZER INC.
    Inventors: Aaron Craig BURNS, Michael Raymond COLLINS, Samantha Elizabeth GREASLEY, Robert Louis Hoffman, Peter Qinhua HUANG, Robert Steven Kania, Pei-Pei KUNG, Maria Angelica LINTON, Lakshmi Sourirajan NARASIMHAN, Paul Francis RICHARDSON, Daniel Tyler RICHTER, Graham SMITH
  • SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
    Publication number: 20170298048
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
  • Cycloalkyl-Linked Diheterocycle Derivatives
    Publication number: 20170050958
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 23, 2017
    Applicant: PFIZER INC.
    Inventors: Aaron Craig BURNS, Michael Raymond COLLINS, Samantha Elizabeth GREASLEY, Robert Louis Hoffman, Peter Qinhua HUANG, Robert Steven Kania, Pei-Pei KUNG, Maria Angelica LINTON, Lakshmi Sourirajan NARASIMHAN, Paul Francis RICHARDSON, Daniel Tyler RICHTER, Graham SMITH
  • SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
    Publication number: 20160376254
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicant: Pfizer Inc.
    Inventors: Michael Raymond COLLINS, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
  • Substituted dihydroisoquinolinone compounds
    Patent number: 9481666
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: November 1, 2016
    Assignee: PFIZER INC.
    Inventors: Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Scott Channing Sutton, Martin James Wythes
  • SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
    Publication number: 20150361067
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: June 16, 2015
    Publication date: December 17, 2015
    Applicant: PFIZER INC.
    Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
  • Macrocyclic derivatives for the treatment of diseases
    Patent number: 9133215
    Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: September 15, 2015
    Assignee: Pfizer Inc.
    Inventors: Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
  • MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
    Publication number: 20140135339
    Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 15, 2014
    Applicant: PFIZER INC.
    Inventors: Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
  • Macrocyclic derivatives for the treatment of diseases
    Patent number: 8680111
    Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: March 25, 2014
    Assignee: Pfizer Inc.
    Inventors: Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
  • 4-methylpyridopyrimidinone compounds
    Patent number: 8633204
    Abstract: The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-K?).
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: January 21, 2014
    Assignee: Pfizer Inc.
    Inventors: Hengmiao Cheng, Dilip Bhumralkar, Klaus Ruprecht Dress, Jacqui Elizabeth Hoffman, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Michael Bruno Plewe, Khanh Tuan Tran
  • MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
    Publication number: 20130252961
    Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 26, 2013
    Applicant: PFIZER INC.
    Inventors: Simon BAILEY, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
  • 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS
    Publication number: 20120309775
    Abstract: The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-K?).
    Type: Application
    Filed: August 16, 2012
    Publication date: December 6, 2012
    Applicant: PFIZER INC
    Inventors: Hengmiao CHENG, Dilip BHUMRALKAR, Klaus Ruprecht DRESS, Jacqui Elizabeth HOFFMAN, Mary Catherine JOHNSON, Robert Steven KANIA, Phuong Thi Quy LE, Mitchell David NAMBU, Mason Alan PAIRISH, Michael Bruno PLEWE, Khanh Tuan TRAN
  • 4-methylpyridopyrimidinone compounds
    Patent number: 8273755
    Abstract: The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-K?).
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: September 25, 2012
    Assignee: Pfizer Inc
    Inventors: Hengmiao Cheng, Dilip Bhumralkar, Klaus Ruprecht Dress, Jacqui Elizabeth Hoffman, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Michael Bruno Plewe, Khanh Tuan Tran
  • Quinoline derivatives
    Patent number: 7923457
    Abstract: The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: April 12, 2011
    Assignee: Agouron Pharmaceuticals Inc.
    Inventors: Yufeng Hong, Robert Steven Kania
  • Pyrazole compounds as RAF inhibitors
    Patent number: 7772246
    Abstract: The present invention is directed to compounds of Formula (I), and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: August 10, 2010
    Assignee: Pfizer Inc.
    Inventors: Jingrong Jean Cui, Judith Gail Deal, Danlin Gu, Chuangxing Guo, Mary Catherine Johnson, Robert Steven Kania, Susan Elizabeth Kephart, Maria Angelica Linton, Indrawan James McAlpine, Mason Alan Pairish, Cynthia Louise Palmer
  • Triazolopyrazine derivatives
    Patent number: 7732604
    Abstract: The invention relates to compounds of the formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: June 8, 2010
    Assignee: Pfizer Inc.
    Inventors: Hengmiao Cheng, Jingrong Jean Cui, Jacqui Elizabeth Hoffman, Lei Jia, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Bich Tran-Dubé
  • 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS
    Publication number: 20100137279
    Abstract: The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-K?).
    Type: Application
    Filed: February 9, 2010
    Publication date: June 3, 2010
    Applicant: Pfizer Inc.
    Inventors: Hengmiao Cheng, Dilip Bhumralkar, Klaus Ruprecht Dress, Jacqui Elizabeth Hoffman, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Michael Bruno Plewe, Khanh Tuan Tran
  • TRIAZOLOPYRAZINE DERIVATIVES
    Publication number: 20100105656
    Abstract: The invention relates to compounds of the formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    Type: Application
    Filed: January 4, 2010
    Publication date: April 29, 2010
    Inventors: Hengmiao Cheng, Jingrong Jean Cui, Jacqui Elizabeth Hoffman, Lei Jia, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Bich Tran-Dubé